论文部分内容阅读
依诺昔酮(Enoximone)是一个兼有正性肌力作用和血管扩张作用的新型强心药,可静注或口服,临床上试用于充血性心力衰竭。本品治疗指数大于洋地黄毒甙作用机理:活体内和试管内研究证明,依诺昔酮的心血管作用是直接的,不经α或β受体、H_1或H_2组胺受体胆碱能受体、Ca~(++)-ATP酶、Mg~(++)-ATP酶、腺苷酸环化酶等兴奋或Na~+、K~+-ATP酶抑制的介导。已证明,本品对狗心的Ⅳ型磷酸二酯酶有特异性抑制作用;当心室肌正性肌力作用达到峰值时,cAMP含量增加。这可能与正
Enoximone is a new type of cardiotonic drug with positive inotropic and vasodilating effects. It can be administered intravenously or orally and clinically for congestive heart failure. This product therapeutic index greater than digoxin mechanism of action: in vivo and in vitro studies have shown that cardiovascular effects of enoxapril is direct, without the alpha or beta receptors, Hl or H 2 histamine receptors cholinergic Receptor, Ca ~ (++) - ATPase, Mg ~ (++) - ATPase, adenylyl cyclase and other stimuli or Na ~ + and K ~ + -ATPase inhibition. It has been shown that this product has a specific inhibitory effect on type IV phosphodiesterase in dog hearts; cAMP levels increase when the positive inotropic effect of ventricular myocytes reaches its peak. This may be positive